The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Open accessAbstract
BACKGROUND: Acute respiratory infections (ARIs) comprise a large and heterogeneous group of infections including bacterial, viral and other aetiologies. In recent years, procalcitonin - the prohormone of calcitonin - has emerged as a promising marker for the diagnosis of bacterial infections and for improving decisions about antibiotic therapy. Several randomised controlled trials (RCTs) have demonstrated the feasibility of using procalcitonin for starting and stopping antibiotics in different patient populations with acute respiratory infections and different settings ranging from primary care to emergency departments (EDs), hospital wards and intensive care units (ICUs). OBJECTIVES: The aim of this systematic review based on individual patient data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 2) which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to May 2011) and EMBASE (1974 to May 2011) to identify suitable trials. SELECTION CRITERIA: We included RCTs of adult participants with ARIs who received an antibiotic treatment either based on a procalcitonin algorithm or usual care/guidelines. Trials were excluded if they exclusively focused on paediatric patients or if they used procalcitonin for another purpose than to guide initiation and duration of antibiotic treatment. DATA COLLECTION AND ANALYSIS: Two teams of review authors independently evaluated the methodology and extracted data from primary studies. The primary endpoints were all-cause mortality and treatment failure at 30 days. For the primary care setting, treatment failure was defined as death, hospitalisation, ARI-specific complications, recurrent or worsening infection, and patients reporting any symptoms of an ongoing respiratory infection at follow-up. For the ED setting, treatment failure was defined as death, ICU admission, re-hospitalisation after index hospital discharge, ARI-associated complications, and recurrent or worsening infection within 30 days of follow-up. For the ICU setting, treatment failure was defined as death within 30 days of follow-up. Secondary endpoints were antibiotic use (initiation of antibiotics, duration of antibiotics and total exposure to antibiotics (total amount of antibiotic days divided by total number of patients)), length of hospital stay for hospitalised patients, length of ICU stay for critically ill patients, and number of days with restricted activities within 14 days after randomisation for primary care patients.For the two co-primary endpoints of all-cause mortality and treatment failure, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable hierarchical logistic regression. The hierarchical regression model was adjusted for age and clinical diagnosis as fixed-effect. The different trials were added as random-effects into the model. We fitted corresponding linear regression models for antibiotic use. We conducted sensitivity analyses stratified by clinical setting and ARI diagnosis to assess the consistency of our results. MAIN RESULTS: We included 14 trials with 4221 participants. There were 118 deaths in 2085 patients (5.7%) assigned to procalcitonin groups compared to 134 deaths in 2126 control patients (6.3%) (adjusted OR 0.94, 95% CI 0.71 to 1.23). Treatment failure occurred in 398 procalcitonin group patients (19.1%) and in 466 control patients (21.9%). Procalcitonin guidance was not associated with increased mortality or treatment failure in any clinical setting, or ARI diagnosis. These results proved robust in various sensitivity analyses. Total antibiotic exposure was significantly reduced overall (median (interquartile range) from 8 (5 to 12) to 4 (0 to 8) days; adjusted difference in days, -3.47, 95% CI -3.78 to -3.17, and across all the different clinical settings and diagnoses. AUTHORS' CONCLUSIONS: Use of procalcitonin to guide initiation and duration of antibiotic treatment in patients with ARI was not associated with higher mortality rates or treatment failure. Antibiotic consumption was significantly reduced across different clinical settings and ARI diagnoses. Further high-quality research is needed to confirm the safety of this approach for non-European countries and patients in intensive care. Moreover, future studies should also establish cost-effectiveness by considering country-specific costs of procalcitonin measurement and potential savings in consumption of antibiotics and other healthcare resources, as well as secondary cost savings due to lower risk of side effects and reduced antimicrobial resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359
Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P., & Lacroix, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421997 · Cited by 1,787
Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Self-citationChrist-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, M., & Müller, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15591-8 · Cited by 1,096
Self-citationSchuetz, P., Christ-Crain, M., Thomann, R., Falconnier, C., Wolbers, M., Widmer, I., Neidert, S., Fricker, T., Blum, C., Schild, U., et al. (2009) · JAMA · doi:10.1001/jama.2009.1297 · Cited by 959
Self-citationProcalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
Self-citation
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Understanding the mechanisms and drivers of antimicrobial resistance
Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P. J., & Piddock, L. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00473-0 · Cited by 2,611
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Metadata
- Authors
- Schuetz, P., Müller, B., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Kristoffersen, K. B., Burkhardt, O., Welte, T., Schroeder, S., Nobre, V., Wei, L., Bhatnagar, N., Bucher, H. C., & Briel, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2012-09-12
- Issue
- 9
- Pages
- CD007498-CD007498
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4238786993
- Cited by
- 264
- References
- 55
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. https://app.cochat.ai/papers/10.1002/14651858.cd007498.pub2
- The paper
- Schuetz, P., Müller, B., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Kristoffersen, K. B., Burkhardt, O., Welte, T., Schroeder, S., Nobre, V., Wei, L., Bhatnagar, N., Bucher, H. C., & Briel, M. (2012). Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007498.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.